Lyell Immunopharma, Inc. (LYEL)
NASDAQ: LYEL · Real-Time Price · USD
0.950
+0.033 (3.64%)
At close: Nov 22, 2024, 4:00 PM
0.998
+0.048 (5.00%)
After-hours: Nov 22, 2024, 7:22 PM EST
Lyell Immunopharma Revenue
Lyell Immunopharma had revenue of $34.00K in the quarter ending September 30, 2024, with 36.00% growth. This brings the company's revenue in the last twelve months to $63.00K, down -99.87% year-over-year. In the year 2023, Lyell Immunopharma had annual revenue of $130.00K, down -99.85%.
Revenue (ttm)
$63.00K
Revenue Growth
-99.87%
P/S Ratio
n/a
Revenue / Employee
$281
Employees
224
Market Cap
265.26M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 130.00K | -84.55M | -99.85% |
Dec 31, 2022 | 84.68M | 74.03M | 695.15% |
Dec 31, 2021 | 10.65M | 2.89M | 37.31% |
Dec 31, 2020 | 7.76M | 7.10M | 1,080.52% |
Dec 31, 2019 | 657.00K | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
ModivCare | 2.79B |
Zynex | 193.67M |
LifeMD | 193.06M |
Anika Therapeutics | 164.17M |
Pulmonx | 79.30M |
Mersana Therapeutics | 34.84M |
Fate Therapeutics | 13.45M |
Ocugen | 4.70M |
LYEL News
- 18 days ago - Lyell Announces Presentation of Initial Clinical Data from the Phase 1-2 Clinical Trial of IMPT-314 for the treatment of B-cell Lymphoma at the 2024 American Society of Hematology (ASH) Annual Meeting - GlobeNewsWire
- 23 days ago - Lyell Immunopharma Completes Acquisition of ImmPACT Bio - GlobeNewsWire
- 4 weeks ago - Lyell Immunopharma: Oversold And Poised For A Turning Point To Growth - Seeking Alpha
- 4 weeks ago - Lyell Immunopharma to Acquire ImmPACT Bio and Prioritizes its Pipeline to Focus on Next-Generation CAR T-cell Therapies - GlobeNewsWire
- 7 weeks ago - Lyell Immunopharma Announces the Acceptance Abstracts for Presentation at 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting - GlobeNewsWire
- 2 months ago - Lyell Immunopharma Announces Participation in Goldman Sachs Cell Therapy Day - GlobeNewsWire
- 3 months ago - Lyell Immunopharma Announces Participation in September Investor Conferences - GlobeNewsWire
- 3 months ago - Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2024 - GlobeNewsWire